NCT06477406Active, not recruitingPhase 2
Evaluating the Impact of a Novel Cannabinoid Product for Endometriosis
Source: ClinicalTrials.gov · Last updated 30 Sept 2026
Brief summary (registry, in English)
Despite the proliferation of cannabis and cannabinoid products in recent years, little research has been done to determine the impact of these products on womens health conditions, including endometriosis. This study is designed to assess the impact of a custom-formulated, hemp-derived, full-spectrum, high-CBD product vs. placebo on clinical symptoms and biomarkers over the course of 12 weeks of treatment in patients with endometriosis. This project will provide information that does not currently exist on the potential efficacy of a cannabinoid-based sublingual product for endometriosis.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 21 Jun 2024
- Start date
- 27 Feb 2024
- Primary completion date
- Dec 2026
- Lead sponsor
- Mclean Hospital
- Diseases
- Endometriosis
- NCT number
- NCT06477406
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 30
- From 27 Feb 2024 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Endorsement of current substance use disorder, psychotic disorder, or an eating disorder
- Presence of a serious or unstable medical illness, including liver, kidney, or cardiovascular disease (hyper/hypotension, cardiac disorders), or neurological disorder (including seizure disorder)
- Neuropathic pain or cancer-related pain
Other
- Non-fluent English speakers
- Currently uses cannabis or cannabinoid products regularly
- Patients will be excluded if they have a positive urine pregnancy test, are trying to become pregnant, or are currently breastfeeding
- Disclosure of a genetic polymorphism affecting CYP2C9 function
Who the study is looking for
- Subject has provided informed consent
- Sex assigned female at birth
- Subject is 21 or older
- Subject is fluent in English
- Subject endorses at least moderate levels of pain at the baseline visit
- Subject endorses having endometriosis
Age in the registry: 21 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| McLean Hospital Coordinator of this site? Confirm its status | Belmont | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.